Recent Publications of Network Partners relevant to ReceptEUR

Publications of Recepteur partners 2008-2000

Publications 2008:

WAUMAN, J., DE SMET A.S., BELSHAM, D. & TAVERNIER, J. IRS4 couples the leptin receptor to multiple signaling pathways. Mol. Endocrinol., 2008 Apr;22(4):965-77

PIESSEVAUX, J., CATTEEUW, D., PEELMAN, F. & TAVERNIER, J. Elongin B/C recruitment regulates substrate binding by CIS. J. Biol. Chem. 2008 May 28.

Lee Y, Hyung SW, Jung HJ, Kim HJ, Staerk J, Constantinescu SN, Chang EJ, Lee ZH, Lee SW, Kim HH. The ubiquitin-mediated degradation of Jak1 modulates osteoclastogenesis by limiting interferon- induced inhibitory signaling.
Blood 2008 Jan 15;111(2):885-93.

Knoops L, Hornakova T, Royer Y, Constantinescu SN, Renauld JC. JAK kinases overexpression promotes in vitro cell transformation. Oncogene. 2008 27(11):1511-9

Metz S, Naeth G, Heinrich PC, Müller-Newen G (2008) Novel inhibitors for murine and human leukemia inhibitory factor based on fused soluble receptors.
J. Biol. Chem. 2008 Mar 7;283(10):5985-95

Haan, S., C. Margue, A. Engrand, C. Rolvering, H. Schmitz-Van de Leur, P. C. Heinrich, I. Behrmann, and C. Haan. 2008. Dual role of the Jak1 FERM- and kinase-domains in cytokine receptor binding and in stimulation-dependent Jak activation. J. Immunol., 180: 998-1007.

Liu J, Plotnikov A, Banerjee A, Suresh Kumar KG, Ragimbeau J, Marijanovic Z, Baker DP, Pellegrini S, Fuchs SY. Ligand-independent pathway that controls stability of interferon alpha receptor. Biochem Biophys Res Commun. 2008 Mar 7;367(2):388-93.

Van Pelt K, Nollet F, Selleslag D, Knoops L, Constantinescu SN, Criel A, Billiet J.
The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human allogeneic transplantation.
Blood. 2008 Aug 1;112(3):921-2. No abstract available.

Knoops L, Hermans C, Ferrant A, Constantinescu SN.
Clinical implications of JAK2 mutations in myeloproliferative disorders. Acta Clin Belg. 2008 Mar-Apr;63(2):93-8.

Kumar KG, Varghese B, Banerjee A, Baker DP, Constantinescu SN, Pellegrini S, Fuchs SY. Basal ubiquitin-independent internalization of interferon alpha receptor is prevented by Tyk2-mediated masking of a linear endocytic motif.
J Biol Chem. 2008 Jul 4;283(27):18566-72. Epub 2008 May 12.
PMID: 18474601 [PubMed - in process]

Gakovic M, Ragimbeau J, Francois V, Constantinescu SN, Pellegrini S. The Stat3-activating Tyk2 V678F mutant does not up-regulate signaling through the type I interferon receptor but confers ligand hypersensitivity to a homodimeric receptor.
J Biol Chem. 2008 Jul 4;283(27):18522-9. Epub 2008 May 2.

Flex E, Petrangeli V, Stella L, Chiaretti S, Hornakova T, Knoops L, Ariola C, Fodale V, Clappier E, Paoloni F, Martinelli S, Fragale A, Sanchez M, Tavolaro S, Messina M, Cazzaniga G, Camera A, Pizzolo G, Tornesello A, Vignetti M, Battistini A, Cavé H, Gelb BD, Renauld JC, Biondi A, Constantinescu SN, Foà R, Tartaglia M. Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia. J Exp Med. 2008 Apr 14;205(4):751-8. Epub 2008 Mar 24.

Dusa A, Stark J, Elliott J, Pecquet C, Poirel HA, Johnston JA, Constantinescu SN.
Substitution of pseudokinase domain residue Val-617 by large non-polar amino acids causes activation of JAK2. J Biol Chem. 2008 May 9;283(19):12941-8. Epub 2008 Mar 6.

Constantinescu SN, Girardot M, Pecquet C. Mining for JAK-STAT mutations in cancer. Trends Biochem Sci. 2008 Mar;33(3):122-31. Review.

Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, Walz C, Reiter A, Podar K, Royer Y, Constantinescu SN, Tomasson MH, Griffin JD, Gilliland DG, Sattler M. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood. 2008 Apr 1;111(7):3751-9. Epub 2008 Jan 23.

Tefferi A, Constantinescu SN. Introduction to 'A special spotlight review series on BCR-ABL-negative myeloproliferative neoplasms'. Leukemia. 2008 Jan;22(1):1.

Lee Y, Hyung SW, Jung HJ, Kim HJ, Staerk J, Constantinescu SN, Chang EJ, Lee ZH, Lee SW, Kim HH. The ubiquitin-mediated degradation of Jak1 modulates osteoclastogenesis by limiting interferon-beta-induced inhibitory signaling. Blood. 2008 Jan 15;111(2):885-93.

Verstrepen L, Bekaert T, Chau TL, Tavernier J, Chariot A, Beyaert R.
TLR-4, IL-1R and TNF-R signaling to NF-kappaB: variations on a common theme. Cell Mol Life Sci. 2008 Jun 6. [Epub ahead of print]

Ward AC, Gits J, Majeed F, Aprikyan AA, Lewis RS, O'Sullivan LA, Freedman M, Shigdar S, Touw IP, Dale DC, Dror Y.
Functional interaction between mutations in the granulocyte colony-stimulating factor receptor in severe congenital neutropenia. Br J Haematol. 2008 May 29. [Epub ahead of print]

Vanhatupa S, Ungureanu D, Paakkunainen M, Silvennoinen O.
MAPK-induced Ser727 phosphorylation promotes SUMOylation of STAT1. Biochem J. 2008 Jan 1;409(1):179-85.

Kreis S, Philippidou D, Margue C, Behrmann I.
IL-24: a classic cytokine and/or a potential cure for cancer? J Cell Mol Med. 2008 May 24 [Epub ahead of print]

Publications 2007:

Touw IP, Van de Geijn G-J. Granulocyte colony-stimulating factor and its receptor in normal myeloid cell development, leukemia and related blood cell disorders. Front. Biosci 2007; 12: 800-815.

Touw, IP and Bontenbal M. Granulocyte colony-stimulating factor: Key (f)actor or innocent bystander in the development of secondary myeloid malignancy? J. Natl. Cancer Inst. 2007; 99: 1-4.

Irandoust MI, Aarts LHJ, Roovers O, Gits J, Erkeland SJ, Touw IP: Suppressor of cytokine signaling 3 controls lysosomal routing of G-CSF receptor. EMBO J. 2007, 2007 26(7):1782-93

LAVENS, D.*, ULRICHTS, P.*, CATTEEUW, D., VANDEKERCKHOVE, J., GEVAERT, K., PEELMAN, F., EYCKERMAN, S. & TAVERNIER, J. The C-terminus of CIS determines its interaction pattern. Biochem. J. 401, 257-267 (2007)

ERKELAND, S.J., AARTS, H.A., ROOVERS, O., KLOMP, A., VALKHOF, M., EYCKERMAN, S., TAVERNIER, J. & TOUW, I.P. WD-repeat and SOCS box-containing protein 2 is a candidate tumor suppressor protein that inhibits granulocyte colony-stimulating factor (G-CSF) signaling. Oncogene 26, 1984-1995 (2007)

UYTTENDAELE, I.*, LEMMENS, I.*, VERHEE, A., DE SMET, A.S., VANDEKERCKHOVE, J., LAVENS, D., PEELMAN, F. & TAVERNIER, J. MAPPIT analysis of STAT5, CIS and SOCS2 binding with the growth hormone receptor Mol. Endocrinol., 21, 2821-2831 (2007)

Staerk J, Kallin A, Royer Y, Diaconu CC, Dusa A, Demoulin JB, Vainchenker W, Constantinescu SN. JAK2, the JAK2 V617F mutant and cytokine receptors. Pathol Biol (Paris). 2007 Mar;55(2):88-91. Review

Hookham MB, Elliott J, Suessmuth Y, Staerk J, Ward AC, Vainchenker W, Percy MJ, McMullin MF, Constantinescu SN, Johnston JA. The myeloproliferative disorder-associated JAK2 V617F mutant escapes negative regulation by suppressor of cytokine signalling 3. Blood. 2007 Jun 1;109(11):4924-9.

Orr SJ, Morgan NM, Buick RJ, Boyd CR, Elliott J, Burrows JF, Jefferies CA, Crocker PR, Johnston JA. SOCS3 targets Siglec 7 for proteasomal degradation and blocks Siglec 7-mediated responses. J Biol Chem. 2007 Feb 9;282(6):3418-22.  (link)

Orr SJ, Morgan NM, Elliott J, Burrows JF, Scott CJ, McVicar DW, Johnston JA.
CD33 responses are blocked by SOCS3 through accelerated proteasomal-mediated turnover. Blood. 2007 Feb 1;109(3):1061-8. (link)

P.Isomäki, T.Alanärä, P. Isohanni, A. Lagerstedt, M. Korpela, T. Moilanen, T. Visakorpi, O. Silvennoinen :The expression of SOCS is altered in rheumatoid arthritis. Rheumatology, 2007, 46, 1538-1546.
M. Sundvall, L. Peri, J.A. Määttä, D. Tvorogod, I. Paatero, M. Savisalo, O. Silvennoinen, Y. Yarden, K. Elenius: Diffrerential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Oncogene, 2007, 26, 6905-6914.

Metz S, Wiesinger M, Vogt M, Lauks H, Schmalzing G, Heinrich PC, Müller-Newen G (2007) Characterization of the interleukin-6 inhibitor IL-6-RFP: Fused receptor domains act as high-affinity cytokine-binding proteins. J. Biol. Chem. 282, 1238-1248  (link)

Wang D, Liu Z, Li Q, Karpurapu M, Kundumani-Sridharan V, Cao H, Dronadula N, Rizvi F, Bajpai AK, Zhang C, Müller-Newen G, Harris KW, Rao GN (2007)
An essential role for gp130 in neointima formation following arterial injury.
Circ. Res. 100, 807-816

Herrmann A, Vogt M, Mönnigmann M, Clahsen T, Sommer U, Haan S, Poli V, Heinrich PC, Müller-Newen G (2007) Nucleocytoplasmic shuttling of persistently activated STAT3 J. Cell. Sci. 120, 3249-3261

Komyod W., M. Böhm, D. Metze, P. C. Heinrich, and I. Behrmann. 2007. Constitutive SOCS3 expression confers a growth advantage to a human melanoma cell line. Mol. Cancer Res., 5:271-281

Kreis, S., G. A. Munz, S. Haan, P. C. Heinrich, and I. Behrmann. 2007a. Cell-density dependent increase of constitutive STAT3 activity in melanoma cells is mediated by Janus kinases. Mol. Cancer Res., 5: 1331-1341.

Kreis, S., D. Philippidou, C. Margue, C. Rolvering, C. Haan, L. Dumontier, J.-C. Renauld; and I. Behrmann. 2007b. Recombinant IL-24 lacks apoptosis-inducing properties in melanoma cells. PLoS ONE, e1300.

Uzé G, Schreiber G, Piehler J, Pellegrini S. The receptor of the type I interferon family. Curr Top Microbiol Immunol. 2007;316:71-95. Review.

Chiu AW, Ehrmantraut M, Richert ND, Ikonomidou VN, Pellegrini S, McFarland HF, Frank JA, Bagnato F. A case study on the effect of neutralizing antibodies to interferon beta 1b in multiple sclerosis patients followed for 3 years with monthly imaging. Clin Exp Immunol 2007 Oct;150(1):61-7.

Marijanovic Z, Ragimbeau J, van der Heyden J, Uzé G, Pellegrini S. Comparable potency of IFNalpha2 and IFNbeta on immediate JAK/STAT activation but differential down-regulation of IFNAR2. Biochem J. 2007 Oct 1;407(1):141-51.

Lemeer S, Ruijtenbeek R, Pinkse MW, Jopling C, Heck AJ, den Hertog J, Slijper M.
Endogenous phosphotyrosine signaling in zebrafish embryos. Mol Cell Proteomics. 2007 Dec;6(12):2088-99. Epub 2007 Aug 14.

Lemeer S, Jopling C, Naji F, Ruijtenbeek R, Slijper M, Heck AJ, den Hertog J.
Protein-tyrosine kinase activity profiling in knock down zebrafish embryos.
PLoS ONE. 2007 Jul 4;2(7):e581.

Ulrichts P, Peelman F, Beyaert R, Tavernier J. MAPPIT analysis of TLR adaptor complexes. FEBS Lett. 2007 Jan 18; (link)

Remoli ME, Ragimbeau J, Giacomini E, Gafa V, Severa M, Lande R, Pellegrini S, Coccia EM. NF-{kappa}B is required for STAT-4 expression during dendritic cell maturation. J Leukoc Biol. 2007 Jan;81(1):355-63. (link)

Haan C, Behrmann I. A cost effective non-commercial ECL-solution for Western blot detections yielding strong signals and low background. J Immunol Methods. 2007 Jan 10;318(1-2):11-9. (link)

Publications 2006:

Zhu QS, Xia L, Mills GB, Lowell CA, Touw IP, Corey SJ. G-CSF induced reactive oxygen species involves Lyn-PI3-kinase-Akt and contributes to myeloid cell growth. Blood. 2006 Mar 1;107(5):1847-56. (link)

Sicinska E, Lee YM, Gits J, Shigematsu H, Yu Q, Rebel VI, Geng Y, Marshall CJ, Akashi K, Dorfman DM, Touw IP, Sicinski P. Essential role for cyclin D3 in G-CSF-driven expansion of neutrophil granulocytes. Mol. Cell. Biol. 2006, 26(21):8052-60. (link)

Gits J, van Leeuwen D, Carroll HP, Touw IP, Ward AC. Multiple pathways contribute to the hyperproliferative responses from truncated granulocyte colony-stimulating factor receptors. Leukemia 2006; 20: 2111-18 (link)

Erkeland SJ, Aarts LH, Irandoust M, Roovers O, Klomp A, Valkhof M, Gits J, Eyckerman S, Tavernier J, Touw IP. Novel role of WD40 and SOCS box protein-2 (Wsb-2) in steady state distribution of granulocyte colony-stimulating factor (G-CSF) receptor and G-CSF-controlled proliferation and differentiation signaling. Oncogene 2006, Sep 25; (link)

Staerk J, Kallin A, Royer Y, Diaconu CC, Dusa A, Demoulin JB, Vainchenker W, Constantinescu SN. JAK2, the JAK2 V617F mutant and cytokine receptors. Pathol Biol (Paris). 2006 Aug 10; (link)

James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W.A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med. 2005 Dec;11(12):546-54. (link)

Staerk J, Lacout C, Sato T, Smith SO, Vainchenker W, Constantinescu SN. An amphipathic motif at the transmembrane-cytoplasmic junction prevents autonomous activation of the thrombopoietin receptor. Blood. 2006 Mar 1;107(5):1864-71. (link)

Peelman F, Couturier C, Dam J, Zabeau L, Tavernier J, Jockers R. New pharmacological perspectives for the leptin receptor. Trends in Pharmacological Sciences, (link)

Piessevaux J, Lavens D, Montoye T, Wauman J, Catteeuw D, Vandekerckhove J, Belsham D, Peelman F, Tavernier J. Functional cross-modulation between SOCS proteins can stimulate cytokine signaling. J Biol Chem. 2006 Nov 3;281(44):32953-66. (link)

Lavens D, Montoye T, Piessevaux J, Zabeau L, Vandekerckhove J, Gevaert K, Becker W, Eyckerman S, Tavernier J. A complex interaction pattern of CIS and SOCS2 with the leptin receptor. J Cell Sci. 2006 Jun 1;119(Pt 11):2214-24. (link)

Peelman F, Iserentant H, De Smet AS, Vandekerckhove J, Zabeau L, Tavernier J. Mapping of binding site III in the leptin receptor and modeling of a hexameric leptin.leptin receptor complex. J Biol Chem. 2006 Jun 2;281(22):15496-504. (link)

Severa M, Remoli ME, Giacomini E, Ragimbeau J, Lande R, Uze G, Pellegrini S, Coccia EM. Differential responsiveness to IFN-alpha and IFN-beta of human mature DC through modulation of IFNAR expression. J Leukoc Biol. 2006 Jun;79(6):1286-94. (link)

Coccia EM, Uze G, Pellegrini S. Negative regulation of type I interferon signaling: facts and mechanisms. Cell Mol Biol (Noisy-le-grand). 2006 May 15;52(1):77-87. Review. (link)

Radtke S, Jorissen A, de Leur HS, Heinrich PC, Behrmann I. A negative regulatory signal within the interbox1/2 region of the oncostatin M receptor prevents efficient surface expression in absence of an associated Janus kinase. J Biol. Chem. 2006 Feb 17;281(7):4024-34. (link)

Haan C, Kreis S, Margue C, Behrmann I. Jaks and cytokine receptors--an intimate relationship. Biochem Pharmacol. 2006 Nov 30;72(11):1538-46. (link)

Deutscher N, Bataille F, Hausmann M, Kiessling S, Muller-Newen G, Leeb SN, Herfarth H, Heinrich PC, Scholmerich J, Rogler G. Functional expression of the interleukin-11 receptor alpha-chain in normal colonic epithelium and colon cancer. Int J Colorectal Dis. 2006 Sep;21(6):573-81. (link)

Valineva T, Yang J, Silvennoinen O. Characterization of RNA helicase A as component of STAT6-dependent enhanceosome. Nucleic Acids Res. 2006;34(14):3938-46. (link)

Kurzer JH, Saharinen P, Silvennoinen O, Carter-Su C. Binding of SH2-B family members within a potential negative regulatory region maintains JAK2 in an active state. Mol Cell Biol. 2006 Sep;26(17):6381-94. (link)

Johnston JA, Burrows JF. De-ubiquitinating enzymes: intracellular signalling and disease. Biochem Soc Trans. 2006 Nov;34(Pt 5):764-9. (link)

Publications 2005:

Wolfler A, Erkeland SJ, Bodner C, Valkhof M, Renner W, Leitner C, Olipitz W, Pfeilstocker M, Tinchon C, Emberger W, Linkesch W, Touw IP, Sill H. A functional single nucleotide polymorphism of the G-CSF receptor gene predisposes to high-risk myelodysplastic syndrome. Blood 2005, 105(9):3731-6. (link)

Vainchenker W, Constantinescu SN. (2005) A unique activating mutation in JAK2 (V617F) is at the origin of Polycythemia Vera and allows a new classification of myeloproliferative diseases. Hematology (Am Soc Hematol Educ Program), 195-200. (link)

James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, Garcon L, Raslova H, Berger R, Bennaceur-Griscelli A, Villeval JL, Constantinescu SN, Casadevall N, Vainchenker W. (2005) A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature, 434(7037), 1144-1148. (link)

James C, Ugo V, Casadevall N, Constantinescu SN, Vainchenker W.A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med. 2005 Dec;11(12):546-54. (link)

Moucadel V, Constantinescu SN. Differential STAT5 signaling by ligand-dependent and constitutively active cytokine receptors. J Biol Chem. 2005 Apr 8;280(14):13364-73.  (link)

Kubatzky KF, Liu W, Goldgraben K, Simmerling C, Smith SO, Constantinescu SN. Structural requirements of the extracellular to transmembrane domain junction for erythropoietin receptor function. J Biol Chem. 2005 Apr 15;280(15):14844-54. (link)

Royer Y, Staerk J, Costuleanu M, Courtoy PJ, Constantinescu SN. Janus kinases affect thrombopoietin receptor cell surface localization and stability. J Biol Chem. 2005 Jul 22;280(29):27251-61. (link)

Eyckerman S, Lemmens I, Catteeuw D, Verhee A, Vandekerckhove J, Lievens S, Tavernier J. Reverse MAPPIT: screening for protein-protein interaction modifiers in mammalian cells. Nat Methods. 2005 Jun;2(6):427-33. (link)

Iserentant H, Peelman F, Defeau D, Vandekerckhove J, Zabeau L, Tavernier J. Mapping of the interface between leptin and the leptin receptor CRH2 domain.J Cell Sci. 2005 Jun 1;118(Pt 11):2519-27. (link)

Zabeau L, Defeau D, Iserentant H, Vandekerckhove J, Peelman F, Tavernier J. Leptin receptor activation depends on critical cysteine residues in its fibronectin type III subdomains. J Biol Chem. 2005 Jun 17;280(24):22632-40. (link)

Montoye T, Lemmens I, Catteeuw D, Eyckerman S, Tavernier J. A systematic scan of interactions with tyrosine motifs in the erythropoietin receptor using a mammalian 2-hybrid approach. Blood. 2005 Jun 1;105(11):4264-71. (link) 

Radtke S, Haan S, Jorissen A, Hermanns HM, Diefenbach S, Smyczek T, Schmitz-Vandeleur H, Heinrich PC, Behrmann I, Haan C. 2005. The Jak1 SH2 domain does not fulfill a classical SH2 function in Jak/STAT signalling but plays a structural role for receptor interaction and upregulation of receptor surface expression. J. Biol. Chem., 280: 25760-25765. (link)

Komyod W, Bauer UM, Heinrich PC, Haan S, Behrmann I. Are STATS arginine-methylated? J Biol Chem. 2005 Jun 10;280(23):21700-5 (link)

Haan S, Keller JF, Behrmann I, Heinrich PC, Haan C. Multiple reasons for an inefficient STAT1 response upon IL-6-type cytokine stimulation. Cell Signal. 2005 Dec;17(12):1542-50. (link)

Giese B, Roderburg C, Sommerauer M, Wortmann SB, Metz S, Heinrich PC, Muller-Newen G. (2005) Dimerization of the cytokine receptors gp130 and LIFR analysed in single cells. J. Cell. Sci. 118, 5129-5140. (link)

Hermanns HM, Muller-Newen G, Heinrich PC, Haan S. Bow to your partner for signaling. Nat Struct Mol Biol. 2005 Jun;12(6):476-8. (link)

Ungureanu D, Silvennoinen O. SLIM trims STATs: E3 ligases provide insight for the specificity in JAK/STAT signalling. Science STKE, 2005(304):pe49. (link)

Ungureanu D, Vanhatupa S, Gronholm J, Palvimo JJ, Silvennoinen O. SUMO-1 conjugation selectively modulates STAT1-mediated gene responses. Blood, 2005, 106, 224-226 (link)

Pesu M, O'Shea J, Hennighausen L, Silvennoinen O. Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders. Mol Interv. 2005 Aug;5(4):211-5. (link)

Valineva T, Yang J, Palovuori R, Silvennoinen O. The transcriptional co-activator protein p100 recruits histone acetyltransferase activity to STAT6 and mediates interaction between the CREB-binding protein and STAT6. J Biol Chem. 2005 Apr 15;280(15):14989-96. (link)

Tannahill GM, Elliott J, Barry AC, Hibbert L, Cacalano NA, Johnston JA. SOCS2 can enhance interleukin-2 (IL-2) and IL-3 signalling by accelerating SOCS3 degradation. Mol Cell Biol. 2005 Oct;25(20):9115-26. (link)

Publications 2004:

van de Geijn GJ, Gits J, Aarts LH, Heijmans-Antonissen C, Touw IP. G-CSF receptor truncations found in SCN/AML relieve SOCS3-controlled inhibition of STAT5 but leave suppression of STAT3. Blood. 2004 Aug 1;104(3):667-74. (link)

Aarts LH, Roovers O, Ward AC, Touw IP. Receptor activation and two distinct COOH-terminal motifs control G-CSF receptor distribution and internalization kinetics. Blood. 2004 Jan 15;103(2):571-9. (link)

Steindler C, Li Z, Algarte M, Alcover A, Libri V, Ragimbeau J, Pellegrini S. 2004. Jamip1 (Marlin-1) defines a family of proteins interacting with JAKs and microtubules. J. Biol. Chem., 279:43168-43177 (link)

Behrmann I, Smyczek T, Heinrich PC, Schmitz-Van de Leur H, Komyod W, Giese B, Muller-Newen G, Haan S, Haan C. 2004. Jak subcellular localisation revisited:The exclusive membrane-localisation of endogenous Janus kinase 1 by cytokine receptor interaction uncovers the Jak/receptor complex to be equivalent to a receptor tyrosine kinase.J. Biol. Chem., 279: 35486-35498. (link)

Pranada AL, Metz S, Herrmann A, Heinrich PC, Muller-Newen G. (2004) Real-time analysis of STAT3 nucleocytoplasmic shuttling. J. Biol. Chem. 279, 15114-15123 (link)

Herrmann A, Sommer U, Pranada AL, Giese B, Kuster A, Haan S, Becker W, Heinrich PC, Muller-Newen G. STAT3 is enriched in nuclear bodies. J Cell Sci. 2004 Jan 15;117(Pt 2):339-49. (link)

Paukku K, Silvennoinen O. STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5. Cytokine Growth Factor Rev. 2004 Dec;15(6):435-55. Review. (link)

Peltola KJ, Paukku K, Aho TL, Ruuska M, Silvennoinen O, Koskinen PJ. Pim-1 kinase inhibits STAT5-dependent transcription via its interactions with SOCS1 and SOCS3. Blood. 2004 May 15;103(10):3744-50. (link)

Elliott J, Johnston JA. SOCS: role in inflammation, allergy and homeostasis. Trends Immunol. 2004 Aug;25(8):434-40. Review. (link)

Burrows JF, McGrattan MJ, Rascle A, Humbert M, Baek KH, Johnston JA. DUB-3, a cytokine-inducible deubiquitinating enzyme that blocks proliferation. J Biol Chem. 2004 Apr 2;279(14):13993-4000. (link)

Johnston JA. Are SOCS suppressors, regulators, and degraders?J Leukoc Biol. 2004 May;75(5):743-8. (link)

Publications 2003:

Seubert N, Royer Y, Staerk J, Kubatzky KF, Moucadel V, Krishnakumar S, Smith SO, Constantinescu SN. (2003) Active and inactive orientations of the transmembrane and cytosolic domains of the erythropoietin receptor dimer. Molecular Cell, 12, 1239-1250. (link)

Shaw MH, Boyartchuk V, Wong S, Karaghiosoff M, Ragimbeau J, Pellegrini S, Muller M, Dietrich WF, Yap GS. A natural mutation in the Tyk2 pseudokinase domain underlies altered susceptibility of B10.Q/J mice to infection and autoimmunity. Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11594-9. (link)

Ragimbeau J, Dondi E, Alcover A, Eid P, Uze G, Pellegrini S. 2003. The tyrosine kinase Tyk2 controls IFNAR1 cell surface expression. EMBO J. 22:537-547 (link)

Muller-Newen G. The cytokine receptor gp130: faithfully promiscuous. Sci STKE. 2003 Sep 23;2003(201):PE40. Review. (link)

Saharinen P, Vihinen M, Silvennoinen O. Autoinhibition of the Jak2 tyrosine kinase is dependent on specific regions in its pseudokinase domain. Mol. Biol. Cell, 2003, 14, 1448-1459 (link)

Johnston JA, O'Shea JJ. Matching SOCS with function. Nat Immunol. 2003 Jun;4(6):507-9. (link)

Seki Y, Inoue H, Nagata N, Hayashi K, Fukuyama S, Matsumoto K, Komine O, Hamano S, Himeno K, Inagaki-Ohara K, Cacalano N, O'Garra A, Oshida T, Saito H, Johnston JA, Yoshimura A, Kubo M. SOCS-3 regulates onset and maintenance of T(H)2-mediated allergic responses. Nat Med. 2003 Aug;9(8):1047-54. (link)

Publications 2002:

Ruijtenbeek R, Versluis C, Heck AJ, Redegeld FA, Nijkamp FP, Liskamp RM. Characterization of a phosphorylated peptide and peptoid and peptoid-peptide hybrids by mass spectrometry. J Mass Spectrom. 2002 Jan;37(1):47-55. (link)

Dekker FJ, de Mol NJ, van Ameijde J, Fischer MJ, Ruijtenbeek R, Redegeld FA, Liskamp RM. Replacement of the intervening amino acid sequence of a Syk-binding diphosphopeptide by a nonpeptide spacer with preservation of high affinity. Chembiochem. 2002 Mar 1;3(2-3):238-42. (link)

Publications 2001:

Eyckerman S, Verhee A, der Heyden JV, Lemmens I, Ostade XV, Vandekerckhove J, Tavernier J. Design and application of a cytokine receptor-based interaction trap. Nature Cell Biology, 3, 1114-1119 (2001). (link)

Cacalano NA, Sanden D, Johnston JA.. Tyrosine-phosphorylated SOCS-3 inhibits STAT activation but binds to p120 RasGAP and activates Ras. Nat Cell Biol. 2001 May;3(5):460-5. (link)

Ruijtenbeek R, Kruijtzer JA, van de Wiel W, Fischer MJ, Fluck M, Redegeld FA, Liskamp RM, Nijkamp FP. Peptoid - peptide hybrids that bind Syk SH2 domains involved in signal transduction. ChemBioChem. 2001 Mar 2;2(3):171-9 (link)

Publications 2000:

de Mol NJ, Plomp E, Fischer MJ, Ruijtenbeek R. Kinetic analysis of the mass transport limited interaction between the tyrosine kinase lck SH2 domain and a phosphorylated peptide studied by a new cuvette-based surface plasmon resonance instrument. Anal Biochem. 2000 Mar 1;279(1):61-70. (link)